• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Melinda Magyari Explores What Registries Reveal About Pediatric MS

Video

Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explores what data registry have shown about factors that are linked with secondary progression in pediatric multiple sclerosis (MS).

Melinda Magyari, MD, PhD, Consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explores what data registry have shown about factors that are linked with secondary progression in pediatric multiple sclerosis (MS).

Transcript

Have registry data revealed any factors related to secondary progression in pediatric MS?

The definition of secondary progression, it's very difficult. So you need to use a composite definition as a proxy. And that's a really hot topic, how to do that composite definition. Also because clinicians are reluctant to define the disease progression because there is no current treatment for secondary progressive MS. However, you see in 2 big, good registries that children progress slowly, but they reach secondary progression phase at a younger age, so 10 years younger than adults.

Related Videos
Joshua K. Sabari, MD
Nicoletta Colombo, MD, PhD
Khush Kharidia, MD
Jo Varshney, PhD, DVM, CEO and founder, VeriSIM Life
Kimberly Westrich, MA, chief strategy officer, National Pharmaceutical Council
Harry Travis, BS Pharm, MBA, president at The Travis Group, LLC
 Brigid Groves, PharmD, MS, vice president, professional affairs, American Pharmacists Association
Chelsea Renfro, PharmD, research and engagement pharmacist, Vanderbilt Specialty Pharmacy
Marc S. Raab, MD, PhD, University Hospital Heidelberg
Chicago skyline with words "CHEST 2025 Recap Chicago, Illinois" | Image credit: SeanPavonePhoto - stock.adobe.com
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.